No Data
No Data
Improved Earnings Required Before HPGC Renmintongtai Pharmaceutical Corporation (SHSE:600829) Stock's 30% Jump Looks Justified
Third Quarter Report 2024
hpgc renmintongtai pharmaceutical corporation (600829.SH) released its performance for the first three quarters, with a net income of 0.206 billion yuan, a 14.36% year-on-year decrease.
hpgc renmintongtai pharmaceutical corporation (600829.SH) disclosed the third quarter report for 2024, achieving revenue of 76...
hpgc renmintongtai pharmaceutical corporation (600829.SH): net income in the first three quarters was 0.206 billion yuan, a year-on-year decrease of 14.36%.
Gelonghui October 21st丨Hpgc Renmintongtai Pharmaceutical Corporation (600829.SH) released the third quarter report, with revenue of 7.678 billion yuan, a year-on-year decrease of 1.88%, net income of 0.206 billion yuan, a year-on-year decrease of 14.36%, non-GAAP net income of 0.19 billion yuan, a year-on-year decrease of 17.16%, and basic earnings per share of 0.3552 yuan.
HPGC Renmintongtai Pharmaceutical (SHSE:600829) May Have Issues Allocating Its Capital
Despite Delivering Investors Losses of 18% Over the Past 5 Years, HPGC Renmintongtai Pharmaceutical (SHSE:600829) Has Been Growing Its Earnings
No Data